A phase 1b study of sovilnesib (an oral KIF18A inhibitor) in subjects with advanced high grade serious ovarian cancer

Sponsor:

Volastra

Sponsor Study ID:

SOVI-2302

CTO #:

104007

NCT Number:

NCT06084416

Phase:

I

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Ovary

Study Objectives:

To compare the safety, tolerability, and preliminary efficacy of sovilnesib at selected dose levels (DLs) to determine the Recommended Phase 2 Dose (RP2D). To further assess the efficacy of sovilnesib. To characterize the pharmacokinetics (PK) of sovilnesib.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)